|
|
| Wednesday 26/04/2023 |
| 18:00 | Registration |
|
| 9th NovAliX Conference - DAY 1 |
| 19:00 | Opening & Welcome Address by NovAliX Conferences Chairman |
Dr Jean-Paul RENAUD
(URANIA THERAPEUTICS, Ostwald, France) |
|
|
SESSION 1: EMERGING TECHNOLOGIES - NEW BIOPHYSICAL APPROACHES FOR MEASURING MOLECULAR INTERACTIONS |
|
|
| Session Chair |
Dr Chaohong SUN
(ABBVIE, North Chicago, United States) |
|
| 19:10 | Kinetic Characterization of Ligand and Antibody Binding to Cell Surface Expressed CCRL2 Using Surface Plasmon Resonance Microscopy (SPRM) (IL01) |
Dr Jonathan BROOKS
(PFIZER, Cambridge, United States) |
|
| 19:40 | Single-Molecule Analysis of Drug-Target Interactions Using a Molecular Forceps (OC01 - virtual presentation) |
Prof. Terence STRICK
(ECOLE NORMALE SUPÉRIEURE, Paris, France) |
|
| 19:55 | Exhibitor Short Presentation
Single Molecule Microscopy-Based Platform for Biophysical Characterization of Drug Candidates (ESP01) |
Dr Tim P. KAMINSKI
(INSINGULO SOLUTIONS AB, Mölndal, Sweden) |
|
| 20:05 | NMR Reporter Assays for the Quantification of Weak-Affinity Receptor–Ligand Interactions (OC02) |
Dr Reto WALSER
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom) |
| |
|
| 20:30 | High-Throughput Protein Analysis and Binding Assays Enabled by IR-MALDESI-MS (IL02) |
Dr Nathaniel ELSEN
(ABBVIE INC., North Chicago, United States) |
|
| 21:00 |
Coffee Break & Exhibition on-site
|
|
|
|
SESSION 2: COVALENT DRUG DISCOVERY |
|
|
| Session Chair |
Dr Daniel WYSS
(MERCK & CO., INC., Morristown, United States) |
|
| 21:30 | Developing Covalent Small Molecules for Protein Targets from Kinases to Transcription Factors (IL03) |
Dr Tinghu ZHANG
(STANFORD, Stanford, United States) |
|
| 22:00 | Covalent Screening and Hit Characterization Methods for Efficient Covalent Drug Discovery (OC03) |
Dr Mela MULVIHILL
(GENENTECH, INC., South San Francisco, United States) |
|
| 22:15 | In-Cell Covalent Inhibitors Discovery (IL04) |
Dr Brent MARTIN
(SCORPION THERAPEUTICS, Boston, United States) |
|
| 22:45 | Exhibitor Short Presentation
Biophysical and Structural Biology Methods Enable Fragment-Based Covalent Ligand Discovery (ESP03) |
Dr Tobias DEIMLING
(CRELUX, A WUXI APPTEC COMPANY, Martinsried, Germany) |
|
| 22:55 | Discovery of the KRAS G12C Covalent Drug Adagrasib and Beyond (OC04) |
Dr Robin GUNN
(MIRATI THERAPEUTICS, San Diego, United States) |
|
| 23:10 | Exhibitor Short Presentation
NovAliX: Drug Discovery from Stand-Alone to Integrated Projects (ESP04) |
Dr Jonathan SETHNA
(NOVALIX, Philadelphia, United States) |
| |
|
| 23:20 | Sequence-Based Design of RNA-Targeted Small Molecules (KL01) |
Prof. Matthew DISNEY
(UF SCRIPPS, Jupiter, United States) |
|
| 00:20 |
Welcome Reception for on-site participants
Sponsored by ALPX
|
|
| |
|
|
| Thursday 27/04/2023 |
| 14:00 | Registration |
|
| 9th NovAliX Conference - DAY 2 |
| SESSION 3: HYBRID METHODS AND TECHNIQUE COMBINATIONS |
|
|
| Session Chair |
Dr Holly SOUTTER
(BROAD INSTITUTE, Cambridge, United States) |
|
| 15:00 | Leishmania Translation Initiation Factor IF4E: a Potential Target for Antiparasitic Drug Development (IL05) |
Dr Mélissa LÉGER-ABRAHAM
(BLAVATNIK INSTITUTE | HARVARD MEDICAL SCHOOL, Boston, United States) |
|
| 15:30 | Drug Discovery for the Oncogenic Protein KRAS on a Model Membrane (OC05) |
Dr Fenneke KLEINJAN
(UHN, Toronto, Canada) |
|
| 15:45 | HDX-MS Use as a Complementary Technique to X-ray Crystallography and Cryo-EM to Better Understand Small Molecule Binding Events (OC06) |
Dr Fabrice CIESIELSKI
(NOVALIX, Illkirch, France) |
|
| 16:05 |
Coffee Break & Exhibition on-site
|
|
|
| 16:35 | Integration of Biophysics and Simulation to Drive Drug Discovery (IL06) |
Dr Holly SOUTTER
(BROAD INSTITUTE, Cambridge, United States) |
|
| 17:05 | Biophysical Characterization of Allosteric Cooperativity in PRMT5 (OC07) |
Prof. Till MAURER
(IDEAYA BIOSCIENCES, South San Francisco, United States) |
|
| 17:20 | Exhibitor Short Presentation
Integrated Use of Biophysics to Improve Data and Decision Quality in Drug Discovery (ESP05) |
Dr Stoyan MILEV
(MALVERN PANALYTICAL INC., Westborough, United States) |
|
| 17:30 | Identification and Characterization of Modulators of DEAH-Box Helicase DHX9 (OC08) |
Dr Ann BORIACK-SJODIN
(ACCENT THERAPEUTICS, Lexington, United States) |
| |
|
| 17:45 | How Ligand-Binding Biophysics can Advance a Small-Molecule Neuroscience Portfolio (KL02) |
Dr Laura SILVIAN
(BIOGEN, Cambridge, United States) |
|
| 18:45 |
Lunch, Networking & Exhibition on-site
|
|
|
| 19:45 |
In-person delegates: Poster Session 1
Virtual delegates: Meet & Greet discussion with Exhibitors |
|
|
|
SESSION 4: BIOPHYSICAL ASSAYS FOR PROTACS AND MOLECULAR GLUES |
|
|
| Session Chair |
Dr Claudio CIFERRI
(GENENTECH, South San Francisco, United States) |
|
| 20:30 | An Integrated Biophysical Approach to Discover Ligands for a Novel E3 Ligase (IL07) |
Dr Nichole O'CONNELL
(KYMERA THERAPEUTICS, Watertown, United States) |
|
| 21:00 | Exhibitor Short Presentation
Cube Biotech Combines Seamless Gene-to-CryoEM Structure Service with its Detergent-Free Membrane Protein Stabilization Platform Technology Native Nanodiscs (ESP06) |
Dr Barbara MAERTENS
(CUBE BIOTECH, Monheim, Germany) |
|
| 21:10 | Targeted MDM2 Degradation Reveals a new Vulnerability for P53-Inactivated Triple Negative Breast Cancer (OC09) |
Dr Joseph SALVINO
(THE WISTAR INSTITUTE, Philadelphia, United States) |
|
| 21:25 |
Coffee Break & Exhibition on-site |
|
|
| 21:55 | Capturing the Flexibility of CRBN Protacs with Cryo-EM (OC10) |
Dr Daniel PETER
(BOEHRINGER INGELHEIM, Vienna, Austria) |
|
| 22:10 | Exhibitor Short Presentation
How Cryo-EM is Transforming Drug Discovery (ESP07) |
Dr Zuben BROWN
(THERMO FISHER SCIENTIFIC, Hillsboro, United States) |
|
| 22:20 | A Covalent BTK Ternary Complex Compatible with Targeted Protein Degradation (IL08) |
Dr Matthew CALABRESE
(PFIZER, Groton, United States) |
| |
|
| 22:55 | Round Table Discussion:
Biophysics and Structural Biology Studies to Assist the Development of PROTACs, Molecular Glues and Beyond
Moderated by |
Dr Katarzyna MARCINKIEWICZ
(NATURE COMMUNICATIONS, New York, NY, United States) |
|
| 23:40 |
In-person delegates: Poster Session 2
Virtual delegates: Meet & Greet discussion with Exhibitors |
|
| |
|
| 01:00 |
Conference Dinner on-site (subject to prior registration) |
|
|
|
| Friday 28/04/2023 |
| 9th NovAliX Conference - DAY 3 |
| SESSION 5: SMALL MOLECULES TARGETING RNA / UNDERSTANDING SMALL-MOLECULE SELECTIVITY TOWARDS RNA |
|
|
| Session Chair |
Dr MariJean EGGEN
(ELI LILLY, Indianapolis, United States) |
|
| 15:00 | Exploring the Undiscovered Country of RNA as a Drug target — Finding Bioactive Ligands against XIST RNA with Affinity-selection MS Screening (IL09) |
Dr Elliott B. NICKBARG
(MERCK & CO., INC., Boston, United States) |
|
| 15:30 | Exhibitor Short Presentation
Atropisomers in Kinase Inhibitors (ESP08) |
Mr Branden LEE
(BIRDOTECH, San Diego, United States) |
|
| 15:40 | Exhibitor Short Presentation
Developments in Sample Preparation and Handling Technology for Crystallography and Cryo-EM (ESP09) |
Ms Joyce FRANK
(MITEGEN, Ithaca, United States) |
|
| 15:50 |
Coffee Break & Exhibition on-site |
|
|
| 16:20 | Exhibitor Short Presentation
Automated Protein Crystallography for Structure Determination and Expert
Small-Molecule Screening (ESP10) |
Dr Andrea PICA
(ALPX, Grenoble, France) |
|
| 16:30 | A Structure-based Approach to Discovering RNA-targeted Small Molecules (IL10) |
Dr Elena MENICHELLI
(ARRAKIS THERAPEUTICS, Waltham, United States) |
| |
|
| 17:00 | Reimagining Druggability using Chemoproteomic Platforms (KL03) |
Prof. Daniel NOMURA
(UC BERKELEY, Berkeley, United States) |
|
| 18:00 | Poster Prizes & Closing Remarks |
|
| |
|
|
|
